Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Apr 25;8(17):28408-28417.
doi: 10.18632/oncotarget.16083.

The prognostic value of histological subtype in patients with metastatic bladder cancer

Cheng Chen  1 , Linkun Hu  1 , Ye Chen  1 , Jianquan Hou  1
Affiliations

The prognostic value of histological subtype in patients with metastatic bladder cancer

Cheng Chen et al. Oncotarget. .

Abstract

We aim to evaluate the prognostic effect of the histological sub-type in patients with metastatic bladder cancer based on the Surveillance Epidemiology and End Results database. A total of 2634 eligible patients were included. The histological subtypes were: transitional cell carcinoma (TCC; 75.2%); adenocarcinoma (3.3%); squamous cell carcinoma (SQCC; 4.1%); and small cell carcinoma (4.3%). A significant association of adenocarcinoma with better survival outcomes (P < 0.015), and that of SQCC with worse outcomes (P < 0.001) was observed. On multivariate analysis, adenocarcinoma was significantly associated with longer and SQCC with shorter survival time as compared to TCC. Overall, 1331 (50.5%) patients had a single metastatic site and 523 (19.9%) had multiple sites involved. Single-site metastasis had a better survival outcome than multiple metastases (P < 0.001). Histological sub-type and presence of multiple metastatic sites are independent predictors of survival time. Prospective, in-depth research is needed to determine optimal therapeutic strategies for different histological subtypes of bladder cancer with different metastatic patterns.

Keywords: distant metastasis; histology; prognosis; survival; urinary bladder neoplasms.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST

None declared.

Figures

Figure 1
Figure 1
Overall survival (A) and bladder cancer-specific survival (B) in bladder cancer patients with transitional cell carcinoma, adenocarcinoma, squamous cell carcinoma, small cell carcinoma with distant metastasis.
Figure 2
Figure 2
Overall survival (A) and bladder cancer-specific survival (B) in bladder cancer patients with single metastatic site vs. multiple metastatic sites.
Figure 3
Figure 3. Metastatic frequency in patients with single-site metastatic bladder cancer by histological subtype
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30. - PubMed
    1. Parkin DM. The global burden of urinary bladder cancer. Scand J Urol Nephrol. 2008. pp. 12–20. - PubMed
    1. Lopez-Beltran A. Bladder cancer: clinical and pathological profile. Scand J Urol Nephrol. 2008. pp. 95–109. - PubMed
    1. Pasquier D, Barney B, Sundar S, Poortmans P, Villa S, Nasrallah H, Boujelbene N, Ghadjar P, Lassen-Ramshad Y, Senkus E, Oar A, Roelandts M, Amichetti M, et al. Small Cell Carcinoma of the Urinary Bladder: A Retrospective, Multicenter Rare Cancer Network Study of 107 Patients. Int J Radiat Oncol Biol Phys. 2015;92:904–10. - PubMed
    1. Koay EJ, Teh BS, Paulino AC, Butler EB. A Surveillance, Epidemiology, and End Results analysis of small cell carcinoma of the bladder: epidemiology, prognostic variables, and treatment trends. Cancer. 2011;117:5325–33. - PubMed